Hemophilia Treatment Drugs Market (Product Type - Recombinant Coagulation Factor Concentrates, Plasma derived Coagulation Factor Concentrates; Disease Indication - Hemophilia A, Hemophilia B, Others; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2030

Description

Hemophilia Treatment Drugs Market - Snapshot

The global hemophilia treatment drugs market was valued at US$ 9,500 Mn in 2017 and is anticipated to reach US$ 15,000 Mn by 2026, expanding at a CAGR of 5% from 2018 to 2026. Increase in R&D investment by key players for developing new drugs for the treatment of hemophilia and rise in demand for long-acting replacement therapies and non-factor therapies are anticipated to fuel the growth of the global market during the forecast period. North America dominated the global market in 2017 owing to the introduction and uptake of new long-acting factors and alternative coagulation promoters and increase in the rate of diagnosis for hemophilia.

The global hemophilia treatment drugs market is driven by government initiatives such as nationwide network of hemophilia treatment centers (HTCs) funded by the Federal Government in the U.S. Many of the HTCs are located at major university medical and research centers. The Federal Government in the U.S. provides funds for more than 100 HTCs. Treatment, education, and support are provided by medical experts at these HTCs. Patients who are provided care and treated at HTCs are less likely to have hospitalization and bleeding complications than those who avail care elsewhere.

The global hemophilia treatment drugs market has been segmented based on product type, disease indication, distribution channel, and region. In terms of product type, the recombinant coagulation factor concentrates segment is projected to account for significant share of the market during the forecast period. New recombinant pipeline agents and gene therapies, such as Fitusiran (phase III trials) and valoctocogene roxaparvovec (phase III candidate), are expected to gain market share during the forecast period. However, some products such as CSL-689 (phase II/III for hemophilia A and hemophilia B) are likely to account for small market share, as these are positioned as on-demand treatments in a market that is increasingly moving toward prophylaxis.

In terms of disease, the global hemophilia treatment drugs market has been classified into hemophilia A, hemophilia B, and others. The hemophilia A segment accounted for major share of the global hemophilia treatment drugs market in 2017. According to the Centers for Disease Control and Prevention (CDC), the exact number of people living with hemophilia globally is not known; however, hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. In terms of distribution channel, the global hemophilia treatment drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held major market share in 2017. The segment is likely to account for leading share of the market during the forecast period.

In terms of region, the global hemophilia treatment drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for major shares of the global hemophilia treatment drugs market in 2017 and the trend is likely to continue from 2018 to 2026. High rate of immigration from tropical regions, increase in health care budgets by governments, and government initiatives to promote hemophilia treatment contributed to the leading shares of these regions. Asia Pacific is projected to be the most attractive market for hemophilia treatment drugs during the forecast period. The market in Asia Pacific is expected to expand at a high CAGR from 2018 to 2026 due to large number of hemophilia patients opting for recombinant coagulation factor concentrates in developing countries such as India and China. The market in Latin America is poised to expand at a moderate growth rate during the forecast period.

Prominent players operating in the global hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire plc, Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi. Shire plc accounted for the largest market share in 2017. The company’s dominance of the market is due to its broad product portfolio, extensive geographical presence, and aggressive acquisition strategies. Shire plc strengthened its market position by acquiring Baxalta in June 2016. Baxalta is a key player in the rare diseases and other specialized disorders segments.

Novo Nordisk A/S accounted for the second largest share of the global hemophilia treatment drugs market in 2017 due to wide range of hemophilia drugs and robust pipeline. However, F. Hoffmann-La Roche, a new entrant in the hemophilia treatment drugs market, is expected to outperform Novo Nordisk during the forecast period. Pfizer held the third largest share of the hemophilia treatment drugs market in 2017.

Rising Danger of Hemophilia Cases will Bring Profitable Growth for the Hemophilia Treatment Drugs Market

The hemophilia treatment drugs market is expected to gain tremendous growth opportunities on the back of the rising cases of hemophilia across the globe. The growing number of cases related to hemophilia around the world will serve as a prominent growth factor during the assessment period of 2018-2026.

Hemophilia is a bleeding disorder. In this condition, a person’s blood does not clot properly which leads to many problems such as spontaneous bleeding and others. This disease is most prevalent among men. Drugs approved for the treatment of hemophilia are known as hemophilia treatment drugs.

According to the Centers for Disease Control and Prevention (CDC), about 400 babies are born with hemophilia A in the U.S. Nearly 33000 males are living with the disorder in the U.S. as per the survey by the CDC. The rising number of patients with hemophilia is directly proportional to the growth of the hemophilia treatment drugs market.

Research and development activities have a vital role in the growth of the hemophilia treatment drugs market. The players in the hemophilia treatment drugs market invest heavily in these activities for developing new formulations that are beneficial for the patients and treat hemophilia more easily and rapidly. Such formulations help in boosting the revenues of the players in the hemophilia treatment drugs market, eventually increasing the growth rate.

Strategic collaborations also play a major role in the growth of the hemophilia treatment drugs market. The players in the hemophilia treatment drugs market indulge in these activities for strengthening their foothold, ultimately increasing the growth prospects across the hemophilia treatment drugs market.

Quick approvals for drugs from regulatory authorities are proving to be game-changers for the hemophilia treatment drugs market. The increasing efforts of the government bodies of numerous countries to provide advanced therapies for hemophilia may also bring immense growth opportunities.

The global hemophilia treatment drugs market has been segmented as follows:

Product

  • Recombinant coagulation factor concentrates
  • Factor VIII
  • Factor IX
  • Others
  • Plasma-derived coagulation factor concentrates
  • Factor VIII
  • Factor IX
  • Others
  • Others

Disease Indication

  • Hemophilia A
  • Hemophilia B
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • South Africa
  • GCC countries
  • Rest of MEA

TABLE OF CONTENT

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Hemophilia Treatment Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Type Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1. Regulatory Scenario by Region/globally
     5.2. Key Mergers & Acquisitions 
     5.3. Pipeline Analysis
     5.4. Clinical Trial Analysis
     5.5. Technological Advancements

6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            6.3.1. Plasma derived coagulation factor concentrates 
                     6.3.1.1. Factor VIII
                     6.3.1.2. Factor IX
                     6.3.1.3. Others
            6.3.2. Recombinant coagulation factor concentrates 
                     6.3.2.1. Factor VIII
                     6.3.2.2. Factor IX
                     6.3.2.3. Others
            6.3.3. Others
     6.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Product Type

7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Hemophilia Treatment Drugs Market Value Forecast by Disease Indication, 2016–2026
            7.3.1. Hemophilia A
            7.3.2. Hemophilia B
            7.3.3. Others
     7.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication

8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            8.3.1. Hospital Pharmacies 
            8.3.2. Retail Pharmacies 
            8.3.3. Online Pharmacies
     8.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel

9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Global Hemophilia Treatment Drugs Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa 
     9.3. Global Hemophilia Treatment Drugs Market Attractiveness, by Country/Region

10. North America Hemophilia Treatment Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. North America Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            10.2.1. Plasma derived coagulation factor concentrates 
                     10.2.1.1. Factor VIII
                     10.2.1.2. Factor IX
                     10.2.1.3. Others
            10.2.2. Recombinant coagulation factor concentrates 
                     10.2.2.1. Factor VIII
                     10.2.2.2. Factor IX
                     10.2.2.3. Others
            10.2.3. Others
     10.3. North America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            10.3.1. Hemophilia A
            10.3.2. Hemophilia B
            10.3.3. Others
     10.4. North America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            10.4.1. Hospital Pharmacies 
            10.4.2. Retail Pharmacies 
            10.4.3. Online Pharmacies
     10.5. North America Hemophilia Treatment Drugs Market Value Forecast by Country, 2016–2026
            10.5.1. U.S.
            10.5.2. Canada
     10.6. North America Hemophilia Treatment Drugs Market Attractiveness Analysis 
                   10.6.1. By Product Type 
            10.6.2. By Disease Indication 
            10.6.3. By Distribution Channel 
            10.6.4. By Country

11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast
     11.1.Introduction
     11.1.1. Key Findings
     11.2. Europe Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            11.2.1. Plasma derived coagulation factor concentrates 
                     11.2.1.1. Factor VIII
                     11.2.1.2. Factor IX
                     11.2.1.3. Others
            11.2.2. Recombinant coagulation factor concentrates 
                     11.2.2.1. Factor VIII
                     11.2.2.2. Factor IX
                     11.2.2.3. Others
            11.2.3. Others
     11.3. Europe Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            11.3.1. Hemophilia A
            11.3.2. Hemophilia B
            11.3.3. Others
     11.4. Europe Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            11.4.1. Hospital Pharmacies 
            11.4.2. Retail Pharmacies 
            11.4.3. Online Pharmacies
     11.5. Europe Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. U.K.
            11.5.3. France
            11.5.4. Spain
            11.5.5. Italy
            11.5.6. Rest of Europe
     11.6. Europe Hemophilia Treatment Drugs Market Attractiveness Analysis 
            11.6.1. By Product Type 
            11.6.2. By Disease Indication 
            11.6.3. By Distribution Channel 
            11.6.4. By Country/Sub-region

12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            12.2.1. Plasma derived coagulation factor concentrates 
                    12.2.1.1. Factor VIII
                     12.2.1.2. Factor IX
                     12.2.1.3. Others
            12.2.2. Recombinant coagulation factor concentrates 
                     12.2.2.1. Factor VIII
                     12.2.2.2. Factor IX
                     12.2.2.3. Others
            12.2.3. Others
     12.3. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            12.3.1. Hemophilia A
            12.3.2. Hemophilia B
            12.3.3. Others
     12.4. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            12.4.1. Hospital Pharmacies 
            12.4.2. Retail Pharmacies 
            12.4.3. Online Pharmacies
     12.5. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            12.5.1. China
            12.5.2. Japan
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis 
            12.6.1. By Product Type 
            12.6.2. By Disease Indication 
            12.6.3. By Distribution Channel 
            12.6.4. By Country/Sub-region

13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2. Latin America Hemophilia Treatment Drugs Market Value Forecast by Product Type, 2016–2026
            13.2.1. Plasma derived coagulation factor concentrates 
                     13.2.1.1. Factor VIII
                     13.2.1.2. Factor IX
                     13.2.1.3. Others
            13.2.2. Recombinant coagulation factor concentrates 
                     13.2.2.1. Factor VIII
                     13.2.2.2. Factor IX
                     13.2.2.3. Others
     13.3. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            13.3.1. Hemophilia A
            13.3.2. Hemophilia B
            13.3.3. Others
     13.4. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            13.4.1. Hospital Pharmacies 
            13.4.2. Retail Pharmacies 
            13.4.3. Online Pharmacies
     13.5. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis 
            13.6.1. By Product Type 
            13.6.2. By Disease Indication 
            13.6.3. By Distribution Channel 
            13.6.4. By Country

14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast
     14.1.Introduction
            14.1.1. Key Findings
     14.2. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016–2026
            14.2.1. Plasma derived coagulation factor concentrates 
                     14.2.1.1. Factor VIII
                     14.2.1.2. Factor IX
                     14.2.1.3. Others
            14.2.2. Recombinant coagulation factor concentrates 
                     14.2.2.1. Factor VIII
                     14.2.2.2. Factor IX
                     14.2.2.3. Others
            14.2.3. Others
     14.3. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016–2026
            14.3.1. Hemophilia A
            14.3.2. Hemophilia B
            14.3.3. Others
     14.4. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            14.4.1. Hospital Pharmacies 
            14.4.2. Retail Pharmacies 
            14.4.3. Online Pharmacies
     14.5. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            14.5.1. GCC Countries
            14.5.2. South Africa
            14.5.3. Rest of Middle East & Africa
     14.6. Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis 
            14.6.1. By Product Type 
            14.6.2. By Disease Indication 
            14.6.3. By Distribution Channel 
            14.6.4. By Country/Sub-region

15. Competition Landscape
     15.1.Market Player – Competition Matrix (by Tier and Size of companies)
     15.2.Market Share Analysis by Company (2017)
     15.3. Company Profiles
            15.3.1. Biotest AG.
                     15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.1.2. Business Overview
                     15.3.1.3. Product Portfolio 
                     15.3.1.4. Financial Overview 
                     15.3.1.5. SWOT Analysis 
                     15.3.1.6. Strategic overview
            15.3.2. Bayer AG
                     15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.2.2. Business Overview
                     15.3.2.3. Product Portfolio 
                     15.3.2.4. Financial Overview 
                     15.3.2.5. SWOT Analysis 
            15.3.3. CSL Limited
                     15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.3.2. Business Overview
                     15.3.3.3. Product Portfolio 
                     15.3.3.4. Financial Overview 
                     15.3.3.5. SWOT Analysis 
                     15.3.3.6. Strategic overview
            15.3.4. F. Hoffmann-La Roche Ltd.
                     15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.4.2. Business Overview
                     15.3.4.3. Product Portfolio 
                     15.3.4.4. Financial Overview 
                     15.3.4.5. SWOT Analysis 
                     15.3.4.6. Strategic overview 
            15.3.5. Kedrion
                     15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.5.2. Business Overview
                     15.3.5.3. Product Portfolio 
                     15.3.5.4. Financial Overview 
                     15.3.5.5. SWOT Analysis 
                     15.3.5.6. Strategic overview
            15.3.6. Novo Nordisk A/S
                                     15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.6.2. Business Overview
                     15.3.6.3. Product Portfolio 
                     15.3.6.4. Financial Overview 
                     15.3.6.5. SWOT Analysis 
                     15.3.6.6. Strategic overview
            15.3.7. Octapharma
                     15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.7.2. Business Overview
                     15.3.7.3. Product Portfolio 
                     15.3.7.4. Financial Overview 
                     15.3.7.5. SWOT Analysis 
                     15.3.7.6. Strategic overview
            15.3.8. Pfizer, Inc
                     15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.8.2. Business Overview
                     15.3.8.3. Product Portfolio 
                     15.3.8.4. Financial Overview 
                     15.3.8.5. SWOT Analysis 
                     15.3.8.6. Strategic overview 
            15.3.9. Sanofi
                     15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.9.2. Business Overview
                     15.3.9.3. Product Portfolio 
                     15.3.9.4. Financial Overview 
                     15.3.9.5. SWOT Analysis 
                     15.3.9.6. Strategic overview
           15.3.10. Shire Plc.
                     15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.10.2. Business Overview
                     15.3.10.3. Product Portfolio 
                     15.3.10.4. Financial Overview 
                     15.3.10.5. SWOT Analysis 
                     15.3.10.6. Strategic overview

Choose License Type

Checkout Inquiry Sample